Targeting the link between ovarian cancer [145], esophageal squamous cell carcinoma [90], and other cancers with AGR2 immunity, we can hypothesize that AGR2 influences the immune microenvironment of patients, suggesting a potential undiscovered link between the two that may impact patient prognosis. This evidence concerns the gene AGR2 and esophageal squamous cell carcinoma.